NVIDIA Corporation

Microsoft Corporation

Gudeng Precision Industrial Co., Ltd.

The likelihood of the AI boom turning out to be a bubble is very high, some market participants believe

Investors in fear of an AI bubble have reverted to dot-com-era defenses. What are they buying?

Innodata Inc.

Is the Google partner and beneficiary of the AI boom still worth buying?

Small cap with big ambitions: Data services firm Innodata up nearly 300% in LTM

Netflix, Inc.

Cathie Wood bought Netflix stock on the drawdown after the report. Should we follow her lead

BioAge Labs, Inc.

Citigroup has upgraded to "buy" shares of small-cap obesity drug developer BioAge Labs, calling the company’s lead molecule promising, with the first-in-human study recently <a href="https://ir.bioagelabs.com/news-releases/news-release-details/bioage-labs-announces-first-participant-dosed-phase-1-clinical">announced</a>. The upgrade <a href="https://finance.yahoo.com/quote/BIOA/?guccounter=1&amp;guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&amp;guce_referrer_sig=AQAAANJzO7qhtq4ftfonGEodVUta3W7CcmJ8wkHgYAForTOSW-XBS4xlKF7KLyQk0L35CoYcX_jqygts2GD4qGMiFBIdNwS4SdNJF98C33sKbOp9lSNggPnmigup5BLKbWDPzB_A28f6kwvxv2u7wovLH2Nc3V4Qa7V3KMWqsBlp24tN">sent</a>&nbsp;the stock up more than 14%. Citigroup believes it could rise a further 70%.

Citigroup upgrades rating, TP on obesity drugmaker BioAge amid upcoming clinical data

Amazon.com, Inc.

Benchmark analyst expects Amazon's stock price to rise by almost 20% more

Amazon had the worst performance among Mag7 stocks. Why does the analyst believe in the company?

Southwest Airlines Co.

Meta Platforms, Inc.

Atlassian Corporation

The bank sees potential for a sharp rise in the securities of a software maker, an airline and one of the bigtechs

Three stocks on the rise: Morgan Stanley names the best investments for the rest of the reporting season

Bank of America Corporation

The index is overheated, the reliance on private equity is growing, and market signals are close to the levels of past peaks

BofA has highlighted five risks that could bring down the S&amp;P 500. What is his advice to investors?

NANO Nuclear Energy Inc.

Silex Systems Limited

Lightbridge Corporation

Many countries are rethinking past limits on nuclear power, given its role in meeting climate targets and bolstering energy security. In the U.S., a series of <a href="https://www.whitehouse.gov/presidential-actions/2025/05/ordering-the-reform-of-the-nuclear-regulatory-commission/#:~:text=(c)%25C2%25A0%2520Facilitate%2520the%2520expansion%2520of%2520American%2520nuclear%2520energy%2520capacity%2520from%2520approximately%2520100%2520GW%2520in%25202024%2520to%2520400%2520GW%2520by%25202050%253B">executive actions</a> in May 2025 set an explicit goal to quadruple nuclear capacity to 400 gigawatts by 2050. They direct federal agencies to strip out unnecessary red tape, accelerate licensing, and spur construction of new reactors and uranium-enrichment facilities. Washington’s aim is to revive the domestic fuel cycle and curb import reliance – note the U.S. still <a href="https://www.eia.gov/uranium/marketing/pdf/2024%20UMAR.pdf">buys</a>&nbsp;roughly 20% of its enriched uranium from Russia.

Which small caps are benefitting from surging demand for nuclear power?

MP Materials Corp.

High dependence on China and geopolitical risks pose a threat to global supply chains

Goldman saw risks to rare earth supply. Three stocks can protect

Investors with a long-term horizon should take a closer look at shares of luxury home goods seller RH, <a href="https://www.fool.com/investing/2025/10/21/why-this-california-based-companys-stock-could-rew/">writes</a>&nbsp;Jeremy Bowman, an analyst at the Motley Fool. The company has faced a number of challenges, leading to a major fall in its share price since the highs reached during the pandemic. But it has several drivers of growth – from expansion into Europe to launching new businesses – that could turn things around, Bowman argues.

The Motley Fool spotlights mid-cap luxury goods retailer RH for patient investors

NeuroSense Therapeutics Ltd.

Noble Capital Markets has initiated coverage of NeuroSense Therapeutics with an “outperform” rating and a target price of $9 per share. Thus, it estimates the micro-cap developer of an amyotrophic lateral sclerosis therapy could rise 620% from current levels. The analysts cite mid-stage trial results of the company’s lead drug PrimeC, which open the way for accelerated registration and earlier commercialization.

Noble initiates on ALS drugmaker NeuroSense with 'outperform', TP for 600% upside


Bank CEO Jamie Dimon estimated the probability of a major correction at 30%

Investment ideas